Skip to main content

Table 6 Summary of Linear mixed model results of MCI and Dementia groups and by APOE ε4 status for plasma TG/HDL ratio and ApoA1, and CSF ApoA1 levels

From: Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease

Analyte

All MCI (n = 106)

MCI APOE4 positive (n = 58)

MCI

APOE4 negative

(n = 48)

All dementia (n = 50)

Dementia APOE4 positive (n = 36)

Dementia

APOE4 negative

(n = 14)

Plasma TG/HDL

Faster

Faster

N.S

Faster

Faster

N.S

Plasma ApoA1

Faster

Faster

Faster

Faster

Faster

Faster

CSF ApoA1

Slower

Faster

N.S

N.S

Faster

N.S

  1. Faster: Higher baseline analyte levels relate to faster progression in one or more of the three cognitive scores: MMSE, CDR-SB, LM
  2. Slower: Higher baseline analyte levels relate to slower progression in one or more of the three cognitive scores: MMSE, CDR-SB, LM
  3. N.S Non-significant results